Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 136%. Earnings per share (EPS) also surpassed analyst estimates by 7.4%. Looking ahead, revenue is expected to decline by 33% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%. Performance of the American Biotechs industry. The company's shares are down 3.9% from a week ago. Before we wrap up, we've discovered 5 warning signs for Cardiff Oncology (2 are a bit unpleasant!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a rec
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRCGlobeNewswire
- RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- CRDF's page on the SEC website